Last reviewed · How we verify
Multiprofen-CC™ plus standard treatment
Multiprofen-CC™ is an anti-inflammatory agent combined with standard treatment to reduce inflammation and improve clinical outcomes.
At a glance
| Generic name | Multiprofen-CC™ plus standard treatment |
|---|---|
| Sponsor | McMaster University |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Multiprofen-CC™ appears to be a formulation combining ibuprofen or a related profen with additional components (CC likely denotes a specific combination or controlled-release formulation) designed to enhance anti-inflammatory efficacy when used alongside standard therapeutic regimens. The exact molecular mechanism and target remain proprietary to McMaster University's development program.
Approved indications
Common side effects
Key clinical trials
- Multiprofen-CC to Reduce Pain in Hand Arthritis (PHASE3)
- Multiprofen-CC™ to Reduce Pain After Total Knee Arthroplasty (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Multiprofen-CC™ plus standard treatment CI brief — competitive landscape report
- Multiprofen-CC™ plus standard treatment updates RSS · CI watch RSS
- McMaster University portfolio CI